Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation
暂无分享,去创建一个
Yu Cheng | Zhiyu Li | Jie Ren | Xi Xu | Yinghe Ma | Hongting Liu | Quanjin Rong | Yifan Feng | Yameng Wang | Ruijia Ge | Jinlei Bian | Jie Ren | Xi Xu | Zhiyu Li | Jinlei Bian | Yifan Feng | Hongting Liu | Quanjin Rong | Yu Cheng | Ruijia Ge | Yameng Wang | Yinghe Ma
[1] Hans-Georg Rammensee,et al. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism , 2008, Cancer Immunology, Immunotherapy.
[2] M. Bower,et al. INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology , 2017, ACS medicinal chemistry letters.
[3] Robert W. Lang,et al. Synthesis of selectively trifluoromethylated pyridine derivaties as potential antihypertensives , 1988 .
[4] G. Turcatti,et al. Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. , 2014, European journal of medicinal chemistry.
[5] Flavia Castellano,et al. Immunosuppressive enzymes in the tumor microenvironment , 2017, FEBS letters.
[6] M. Sono,et al. 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. , 1991, Archives of biochemistry and biophysics.
[7] J. Baell,et al. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.
[8] Jürgen Bajorath,et al. Design and Evaluation of a Molecular Fingerprint Involving the Transformation of Property Descriptor Values into a Binary Classification Scheme , 2003, J. Chem. Inf. Comput. Sci..
[9] Hao-Ze Huang,et al. Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening. , 2014, European journal of medicinal chemistry.
[10] Zhong-Jun Li,et al. Design, synthesis and biological evaluation of novel naphthoquinone derivatives as IDO1 inhibitors. , 2018, European journal of medicinal chemistry.
[11] Shan Qian,et al. IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery , 2016 .
[12] Fang Liu,et al. Discovery and Design of Tricyclic Scaffolds as Protein Kinase CK2 (CK2) Inhibitors through a Combination of Shape-Based Virtual Screening and Structure-Based Molecular Modification , 2013, J. Chem. Inf. Model..
[13] C. Sheridan. IDO inhibitors move center stage in immuno-oncology , 2015, Nature Biotechnology.
[14] Alex Avdeef,et al. Miniaturized Rotating Disk Intrinsic Dissolution Rate Measurement: Effects of Buffer Capacity in Comparisons to Traditional Wood’s Apparatus , 2008, Pharmaceutical Research.
[15] C. Piccirillo,et al. Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives , 2011, Clinical Cancer Research.
[16] Qing Yang,et al. Oren-gedoku-to and its constituents with therapeutic potential in Alzheimer's disease inhibit indoleamine 2, 3-dioxygenase activity in vitro. , 2010, Journal of Alzheimer's disease : JAD.
[17] Qing Yang,et al. Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice. , 2013, Journal of medicinal chemistry.
[18] Paul Labute,et al. The generalized Born/volume integral implicit solvent model: Estimation of the free energy of hydration using London dispersion instead of atomic surface area , 2008, J. Comput. Chem..
[19] Takashi Otsuki,et al. Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[20] Klaus R. Liedl,et al. Minor Groove Binders and Drugs Targeting Proteins Cover Complementary Regions in Chemical Shape Space , 2011, J. Chem. Inf. Model..
[21] D. Munn,et al. IDO and tolerance to tumors. , 2004, Trends in molecular medicine.
[22] Tao Lu,et al. An Integrated Virtual Screening Approach for VEGFR-2 Inhibitors , 2013, J. Chem. Inf. Model..
[23] R. W. Lang,et al. Synthesis of Selectively Trifluoromethylated Pyridine Derivatives as Potential Antihypertensives. , 1988 .
[24] Kazuo Suzuki,et al. Interferon-γ Regulates the Proliferation and Differentiation of Mesenchymal Stem Cells via Activation of Indoleamine 2,3 Dioxygenase (IDO) , 2011, PloS one.
[25] Malgorzata N. Drwal,et al. Combination of ligand- and structure-based methods in virtual screening. , 2013, Drug discovery today. Technologies.
[26] G. Prendergast,et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. , 2007, Cancer research.
[27] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[28] David S. Goodsell,et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..
[29] G. Prendergast,et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy , 2005, Nature Medicine.
[30] G. Prendergast,et al. Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion , 2010, Cancer Immunology, Immunotherapy.
[31] P. Scherle,et al. Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy. , 2009, Current cancer drug targets.
[32] D. Munn,et al. Ido expression by dendritic cells: tolerance and tryptophan catabolism , 2004, Nature Reviews Immunology.
[33] Stewart B Kirton,et al. Prediction of binding modes for ligands in the cytochromes P450 and other heme‐containing proteins , 2005, Proteins.
[34] S. Paul,et al. Nitrobenzofurazan derivatives of N'-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1. , 2016, European journal of medicinal chemistry.
[35] Jinlei Bian,et al. Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: Design, synthesis, and in vivo antitumor evaluation. , 2016, Bioorganic & medicinal chemistry.
[36] Paul L A Popelier,et al. The hydration of serine: multipole moments versus point charges. , 2014, Physical chemistry chemical physics : PCCP.
[37] Tetsuya Kohno,et al. Crystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors. , 2014, ACS medicinal chemistry letters.
[38] Su-Ying Wu,et al. Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1. , 2016, Journal of medicinal chemistry.
[39] P. Hawkins,et al. Comparison of shape-matching and docking as virtual screening tools. , 2007, Journal of medicinal chemistry.
[40] Simona Distinto,et al. How To Optimize Shape-Based Virtual Screening: Choosing the Right Query and Including Chemical Information , 2009, J. Chem. Inf. Model..
[41] C. Uyttenhove,et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.
[42] Qian Wang,et al. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. , 2009, Journal of medicinal chemistry.
[43] H. Koblish,et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.
[44] Charles L. Brooks,et al. Detailed analysis of grid‐based molecular docking: A case study of CDOCKER—A CHARMm‐based MD docking algorithm , 2003, J. Comput. Chem..
[45] S. Kaiser,et al. Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate. , 2017, Journal of medicinal chemistry.
[46] Olivier Michielin,et al. Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. , 2015, Journal of medicinal chemistry.
[47] David J. Freeman,et al. Reinstalling Antitumor Immunity by Inhibiting Tumor-Derived Immunosuppressive Molecule IDO through RNA Interference1 , 2006, The Journal of Immunology.
[48] Charles J. Link,et al. Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. , 2013 .
[49] Tingjun Hou,et al. Development and Evaluation of an Integrated Virtual Screening Strategy by Combining Molecular Docking and Pharmacophore Searching Based on Multiple Protein Structures , 2013, J. Chem. Inf. Model..
[50] Paolo Vicini,et al. Abstract 4863: PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors , 2016 .
[51] O. Hayaishi,et al. Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. , 1986, The Journal of biological chemistry.
[52] O. Hayaishi,et al. Properties and function of indoleamine 2,3-dioxygenase. , 1976, Journal of biochemistry.